Kovack Advisors’s BioLineRX BLRX Stock Holding History

Kovack Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-24	Closed	-$30K	–	220
2015 Q1	$30K	Buy	+24	New	+$29.5K	0.03%	165

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NCCM

Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Kovack Advisors's BLRX Position: Q2 2015 in Review

Kovack Advisors sold out of BioLineRX (BLRX) in Q2 2015, closing a stake of 24 shares — an estimated $30K sold.

Kovack Advisors first reported a position in BLRX in Q1 2015 and held it in 1 quarter. The position peaked at $30K in Q1 2015. 20 funds tracked by Wall St. Rank hold BLRX as of Q2 2015.

Kovack Advisors reported no remaining BioLineRX position as of Q2 2015 after selling out during the quarter.
Kovack Advisors sold 24 BioLineRX shares in Q2 2015, an estimated $30K.
Kovack Advisors first reported a position in BioLineRX in Q1 2015 and held it in 1 quarter.
Kovack Advisors's BioLineRX position peaked at $30K in Q1 2015.
20 funds tracked by Wall St. Rank held BioLineRX as of Q2 2015.

Based on Kovack Advisors's 13F filing for Q2 2015, filed 6 Nov 2018.